A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tanespimycin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Apr 2017 Biomarkers information updated
- 15 Sep 2009 Actual end date (1 Dec 2008) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Additional lead trial centres and lead trial investigator Elisabeth I. Heath as reported by ClinicalTrials.gov.